Lista de obras -

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects

artículo científico publicado en 2017

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

artículo científico publicado en 2015

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines

artículo científico publicado en 2013

Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.

artículo científico publicado en 2018

Angiogenesis drives psoriasis pathogenesis

artículo científico publicado en 2009

Angiogenesis: the new potential target for the therapy of psoriasis?

artículo científico publicado en 2008

Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)

scientific journal article

Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors

artículo científico publicado en 2008

EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion

artículo científico publicado en 2009

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect ⬇️

artículo científico publicado el 1 de junio de 2012

Immunological effects of a novel RNA-based adjuvant in liver cancer patients

artículo científico publicado en 2016

Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants

artículo científico publicado en 2004

Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis

artículo científico publicado en 2004

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.

artículo científico publicado en 2002

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

artículo científico publicado en 2014

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

scientific article published on 21 February 2019

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines

artículo científico publicado en 2017

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

artículo científico publicado en 2015

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

article

Self-adjuvanted RNActive® vaccines provide a promising platform for combination therapies with checkpoint inhibitors.

artículo científico publicado en 2014

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

artículo científico publicado en 2016

Signaling mechanism of extracellular RNA in endothelial cells

artículo científico publicado en 2009

Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation

scientific article published on 01 May 2007

Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice.

artículo científico publicado en 2008

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

artículo científico publicado en 2017

mRNA Cancer Vaccines

artículo científico publicado en 2016

mRNA mediates passive vaccination against infectious agents, toxins, and tumors.

artículo científico publicado en 2017

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors

artículo científico publicado en 2014

mRNA: A Novel Avenue to Antibody Therapy?

artículo científico publicado en 2019

Lista de obras de

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines

Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.

Angiogenesis drives psoriasis pathogenesis

Angiogenesis: the new potential target for the therapy of psoriasis?

Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)

Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors

EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect ⬇️

Immunological effects of a novel RNA-based adjuvant in liver cancer patients

Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants

Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

Self-adjuvanted RNActive® vaccines provide a promising platform for combination therapies with checkpoint inhibitors.

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

Signaling mechanism of extracellular RNA in endothelial cells

Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation

Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice.

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

mRNA Cancer Vaccines

mRNA mediates passive vaccination against infectious agents, toxins, and tumors.

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors

mRNA: A Novel Avenue to Antibody Therapy?